Cargando…

Pro-inflammatory proteins S100A9 and tumor necrosis factor-α suppress erythropoietin elaboration in myelodysplastic syndromes

Accumulating evidence implicates innate immune activation in the pathobiology of myelodysplastic syndromes. A key myeloid-related inflammatory protein, S100A9, serves as a Toll-like receptor ligand regulating tumor necrosis factor-α and interleukin-1β production. The role of myelodysplastic syndrome...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cluzeau, Thomas, McGraw, Kathy L., Irvine, Brittany, Masala, Erico, Ades, Lionel, Basiorka, Ashley A., Maciejewski, Jaroslaw, Auberger, Patrick, Wei, Sheng, Fenaux, Pierre, Santini, Valeria, List, Alan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5709100/ https://www.ncbi.nlm.nih.gov/pubmed/28983059 http://dx.doi.org/10.3324/haematol.2016.158857

Ejemplares similares

TP53 and MDM2 single nucleotide polymorphisms influence survival in non-del(5q) myelodysplastic syndromes
por: McGraw, Kathy L., et al.
Publicado: (2015)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
por: McGraw, Kathy L., et al.
Publicado: (2014)

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
por: Wang, Chen, et al.
Publicado: (2021)

Erythropoietin Receptor Signaling Is Membrane Raft Dependent
por: McGraw, Kathy L., et al.
Publicado: (2012)

How I Treat TP53-Mutated Acute Myeloid Leukemia and Myelodysplastic Syndromes
por: Loschi, Michael, et al.
Publicado: (2022)

Unraveling the Pathogenesis of MDS: The NLRP3 Inflammasome and Pyroptosis Drive the MDS Phenotype
por: Sallman, David A., et al.
Publicado: (2016)

Naïve T-cells in Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency
por: Yang, Lili, et al.
Publicado: (2012)

BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia
por: Vidal, Valérie, et al.
Publicado: (2017)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Serum Inflamma-miR Signature: A Biomarker of Myelodysplastic Syndrome?
por: Mariani, Marianna, et al.
Publicado: (2020)

Acadesine Circumvents Azacitidine Resistance in Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2019)

Molecular Pathogenesis of Myelodysplastic Syndromes
por: Visconte, Valeria, et al.
Publicado: (2014)

The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
por: McGraw, K L, et al.
Publicado: (2015)

Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures
por: Masala, Erico, et al.
Publicado: (2018)

Erythropoietin Interacts with Specific S100 Proteins
por: Kazakov, Alexey S., et al.
Publicado: (2022)

The effects of continued azacitidine treatment cycles on response in higher risk patients with myelodysplastic syndromes: an update
por: Silverman, LR, et al.
Publicado: (2008)

Preclinical modeling of myelodysplastic syndromes
por: Rouault-Pierre, K, et al.
Publicado: (2017)

Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858
por: Eksioglu, Erika A., et al.
Publicado: (2017)

Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
por: Ma, Wanlong, et al.
Publicado: (2010)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Molecular predictors of response in patients with myeloid neoplasms treated with lenalidomide
por: Negoro, Eiju, et al.
Publicado: (2016)

Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis
por: Balleari, Enrico, et al.
Publicado: (2019)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes
por: Park, Sophie, et al.
Publicado: (2019)

Erythropoietin inhibits osteoblast function in myelodysplastic syndromes via the canonical Wnt pathway
por: Balaian, Ekaterina, et al.
Publicado: (2018)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Somatic gene mutations expose cytoplasmic DNA to co-opt the cGAS/STING/NLRP3 axis in myelodysplastic syndromes
por: McLemore, Amy F., et al.
Publicado: (2022)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

Eprenetapopt Plus Azacitidine in TP53-Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Phase II Study by the Groupe Francophone des Myélodysplasies (GFM)
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Synergistic effects of PRIMA-1(Met) (APR-246) and 5-azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia
por: Maslah, Nabih, et al.
Publicado: (2020)

Targeted resequencing analysis of 31 genes commonly mutated in myeloid disorders in serial samples from myelodysplastic syndrome patients showing disease progression
por: Pellagatti, A, et al.
Publicado: (2016)

TP53 Alterations in Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Rahmé, Ramy, et al.
Publicado: (2023)

Response Assessment to Erythropoietin-Zeta (Epo-Alpha Biosimilar) Therapy in Low-Risk Myelodysplastic Syndromes
por: Vetro, Calogero, et al.
Publicado: (2022)

Immune dysregulation in myelodysplastic syndrome
por: Sugimori, Chiharu, et al.
Publicado: (2010)

Cytogenetic and molecular predictors of response in patients with myeloid malignancies without del[5q] treated with lenalidomide
por: Sugimoto, Yuka, et al.
Publicado: (2012)

Efficacy and safety of bemcentinib in patients with advanced myelodysplastic neoplasms or acute myeloid leukemia failing hypomethylating agents- the EMSCO phase II BERGAMO trial
por: Kubasch, A. S., et al.
Publicado: (2023)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0gmie8hssfan65uk3ab1b3tt6e